BioEnergenix

BioEnergenix is a clinical-stage biotechnology company dedicated to developing innovative therapies for metabolic and orphan diseases by targeting the AMP-activated protein kinase (AMPK) pathway. The company's lead program, BE-401 (formerly PXL770), is a first-in-class direct AMPK activator that has demonstrated proof-of-concept in Phase 2a trials for NASH and is being advanced for X-linked adrenoleukodystrophy (X-ALD). BioEnergenix also possesses BE-101 (formerly PXL065), a deuterium-stabilized R-pioglitazone, targeting metabolic dysfunction-associated steatohepatitis (MASH). The company was formed through the acquisition of these metabolic assets from Poxel SA, leveraging a deep understanding of mitochondrial and metabolic signaling. BioEnergenix aims to address significant unmet medical needs in both large-market metabolic conditions and rare genetic disorders.